Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.31 |
| ▸ | NT5E | P21589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293429 | 1.00 | ADORA1 (0.32) | ADORA1HTR2BTMIGD3CYP2C9HTR2C | |
| SCHEMBL242801 | 0.87 | ADORA1 (0.37) | ADORA1HTR2BTMIGD3CYP2C9HTR2C | |
| SCHEMBL1401997 | 0.77 | ADORA1 (0.41) | ADORA1HTR2BTMIGD3CYP2C9HTR2C | |
| SCHEMBL243701 | 0.77 | ADORA1 (0.41) | ADORA1HTR2BTMIGD3CYP2C9HTR2C | |
| SCHEMBL240045 | 0.72 | ADORA3 (0.46) | ADORA1HTR2BTMIGD3CYP2C9HTR2C | |
| SCHEMBL4220375 | 0.72 | ADORA3 (0.46) | ADORA1HTR2BTMIGD3CYP2C9HTR2C | |
| SCHEMBL241801 | 0.71 | ADORA3 (0.52) | ADORA1ADORA3ADORA2ANT5E | |
| SCHEMBL239530 | 0.69 | LMNA (0.39) | ADORA1HTR2BTMIGD3HTR2CADORA3 | |
| SCHEMBL1412358 | 0.69 | ADORA1 (0.52) | ADORA1ADORA3ADORA2ANT5E | |
| SCHEMBL1401972 | 0.69 | ADORA1 (0.49) | ADORA1HTR2BTMIGD3CYP2C9HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8163754-B2 | inflammatory or obstructive airways diseases; in combination with an antiinflammatory, bronchodilatory, antihistamine or anti-tussive; N-[4-(6-Amino-2-phenethylamino-purin-9-yl)-2,3-dihydroxy-cyclopentyl]-propionamide | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2292619-A1 | Purine derivatives for use as adenonsin A-2A receptor agonists | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | ADORA1 1271/4885HTR2B 980/4885TMIGD3 4787/4885 |
| US-20080200483-A1 | Purine Derivatives for Use as Adenosin A-2A Receptor Agonists | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885HTR2B 399/4885TMIGD3 2995/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA1 1271/4885HTR2B 980/4885TMIGD3 4787/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | ADORA1 1271/4885HTR2B 980/4885TMIGD3 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.